![Benjamin Strain](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Benjamin J.
Strain worked as Associate Portfolio Manager at The Boston Company Asset Management LLC.
Served as Senior Manager-Investor Relations at Biogen, Inc. Held the position of Head-Investor Relations & Communications at Paratek Pharmaceuticals, Inc. from 2018 to 2021.
Worked as Vice President-Investor Relations & Communications at Foghorn Therapeutics, Inc. from 2021 to 2023.
Served as Head-Investor Relations at Incyte Corp.
from 2023 to 2025.
Completed undergraduate studies at Peter T Paul College of Business & Economics.
Earned an MBA from McCallum Graduate School of Business.
Anciens postes connus de Benjamin Strain
| Sociétés | Poste | Fin |
|---|---|---|
| INCYTE CORPORATION | Investor Relations Contact | 01/01/2025 |
| FOGHORN THERAPEUTICS INC. | Investor Relations Contact | 01/09/2023 |
| PARATEK PHARMACEUTICALS, INC. | Investor Relations Contact | 01/08/2021 |
The Boston Company Asset Management LLC
 The Boston Company Asset Management LLC Investment ManagersFinance The Boston Company Asset Management (TBCAM) offers both traditional and alternative equity investment products that encompass a variety of US, non-US and global strategies. The firm provides investment advice for the following types of strategies: US domestic equity, balanced, non-US equity, emerging markets equity and long/short equity. Portfolios generally are composed of individual securities. TBCAM seeks consistent delivery of alpha across a broad range of investment strategies. They are committed to a value-oriented, research-driven and risk-aware investment approach. TBCAM seeks to identify attractive stocks through rigorous quantitative and fundamental analyses blended with analysis of current business momentum and places controls on sector selection and, if applicable, country selection. Short sales and similar strategies are considered part of their overall investment strategy; however, they are not used across the account base in the management of account assets. The firm may use these strategies for certain accounts consistent with the client's guidelines, objectives, and restrictions. | Gestionnaire de Portefeuille-Actions | 06/01/2009 |
| BIOGEN INC. | Public Communications Contact | - |
Formation de Benjamin Strain
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
20
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
The Boston Company Asset Management LLC
The Boston Company Asset Management LLC Investment ManagersFinance The Boston Company Asset Management (TBCAM) offers both traditional and alternative equity investment products that encompass a variety of US, non-US and global strategies. The firm provides investment advice for the following types of strategies: US domestic equity, balanced, non-US equity, emerging markets equity and long/short equity. Portfolios generally are composed of individual securities. TBCAM seeks consistent delivery of alpha across a broad range of investment strategies. They are committed to a value-oriented, research-driven and risk-aware investment approach. TBCAM seeks to identify attractive stocks through rigorous quantitative and fundamental analyses blended with analysis of current business momentum and places controls on sector selection and, if applicable, country selection. Short sales and similar strategies are considered part of their overall investment strategy; however, they are not used across the account base in the management of account assets. The firm may use these strategies for certain accounts consistent with the client's guidelines, objectives, and restrictions. | Finance |
Incyte Corp.
 Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Peter T Paul College of Business & Economics
 Peter T Paul College of Business & Economics Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Paratek Pharmaceuticals, Inc.
 Paratek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
McCallum Graduate School of Business
 McCallum Graduate School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Foghorn Therapeutics, Inc.
 Foghorn Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops novel drugs to treat cancer and other serious medical disorders | Health Technology |
